Bradykinin, tritiated at the 2,3-prolyl-3,4 position. Bradykinin is the endogenous ligand that activates bradykinin B1 and B2 receptors.
Please enter valid quantity
Please login to add favorites
NULL OR EMPTY CART
|Part Number||Unit Size||List Price||Your Price||Quantity|
|NET706050UC||50 µCi||2476.00 EUR|
|NET706250UC||250 µCi||5700.00 EUR|
You successfully added item(s) to your cart
Bradykinin binds bradykinin B1 and B2 receptors. Bradykinin receptors are GPCRs involved in inflammation, and are potential drug targets for cancer and inflammatory disease.
We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (Bmax), dissociation constants (Kd), association and dissociation rates (kon and koff), and inhibitor constants (Ki) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays.
Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, PerkinElmer has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments.
References for NET706:
|Label Position||Nominally Labeled|
|Product Brand Name||NEN Radiochemicals|
|Shipping Condition||Dry Ice|
|Special Ordering Information||This is a radioactive product - shipping address must have a license to receive radioactive materials.|
|Therapeutic Area||Angiogenesis, Pain, Cardiovascular, Inflammation|
|Unit Size||50 µCi|